NewsBenzingaNeedham réitère son achat sur Vaxcyte, maintient un objectif de prix de 110 dollars Needham réitère son achat sur Vaxcyte, maintient un objectif de prix de 110 dollars Benzinga 2026.09.25 10:15 (GMT+0) Open on Benzinga Other news JD Vance Warns Companies Against 'Cheap' H-1B Replacements: 'We're Not Going to Let You Lay Off American Workers' Baird Maintains Outperform on H.B. Fuller, Lowers Price Target to $65 Baird Maintains Outperform on Charles River, Raises Price Target to $334 Arvinas Q2 2026 Earnings Call Transcript Wall Street's Most Accurate Analysts Spotlight On 3 Tech Stocks Delivering High-Dividend Yields Cantor Fitzgerald Reiterates Overweight on Aurora Innovation, Maintains $12 Price Target
JD Vance Warns Companies Against 'Cheap' H-1B Replacements: 'We're Not Going to Let You Lay Off American Workers'
